Tempus Unicorn is a technology company that has built an operating system to enhance fight against chronic cancer disease. Eric Lefkofsky is the CEO and the co-founder of Tempus. He is also a co-founder partner of Lightbank, a firm that investigates disruptive technologies, and a chairperson of Group Company. Tempus uses optical character recognition, manual curation and natural language in the improvement of cancer efficiency and personalizing cancer care.
The technology company is building a library of molecular and clinical data with an operating system to enhance data accessibility. The physicians are skilled in delivering personalized cancer care for patients through an interactive, analytical and machine-learning platform. Consequently, the company provides therapeutic data, analyzed molecular and genomic sequencing services to empower physicians on how to make real-time and data-driven decisions.
The company occasionally receives financial support from well-wishers to help Tempus in the realization of its goals through advanced medical equipment and better infrastructure. The CEO Eric Lefkofsky on March 2018 confirmed announcement of additional funds amounting eighty million dollars from new and existing investors. The companies that funded include Revolution Growth, New Enterprise Associates and New Investors Trust Co, all with the main agenda of campaigning against cancer and caring for cancer patients.
Tempus has recently experienced rapid growth as a result of the financial support and a need to increase facilities to accommodate as many patients possible to eradicate cancer. With about 400 professional workers, Tempus consistently employs more workers to meet the high demanding task force of the organization.
The company has professional workers determine in proving quality and reliable health services to all patients. Lefkofsky embraces the technology as it is the only way to transform the company. His primary objective is to redefine the use of genomic data in the medical clinic.
The Tempus health company uses clinical data as means learning and analyzing trends in treating cancer. They also partner with physicians and other hospitals to increase current offering by providing access to genomic sequencing with useful analytics and a machine learning platform that also leverages data from, proteomics, single-cell genomics and biological models.